25 September 2024

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

General Meeting Requisition Notice

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that it has received a requisition notice ("Notice") dated 24 September 2024 from Platform Securities Nominees Limited, as the legal holder of 8,643,583 ordinary shares of 0.05p each in the Company, held as nominee on behalf of Seneca Partners.

The cumulative holding includes the interests of Seneca EIS (c/o WCS Nominees Ltd), Seneca Growth Capital and the personal holdings of six individuals connected to Seneca Partners and represents 5.46% of the Company's current issued share capital.

The notice requests the Company's Board of Directors (the "Board") to convene a General Meeting ("Requisitioned GM") under section 303 and 314 of the Companies Act 2006 (the "Act").

A further announcement will be published within the next 21 days once the Board has considered the Notice and the proposed resolutions. In the meantime, the Board advises shareholders to take no action at this stage.

The Notice sets out three ordinary resolutions to be proposed at the Requisitioned GM, which are set out below:

"Proposed Resolution 1: To remove Steen Andersen as a Director of the Company.

Proposed Resolution 2: To remove Frederik Bruhn-Petersen as a Director of the Company.

Proposed Resolution 3: To remove any person appointed by the Board, after the date of this notice, as a Director of the Company."

For further information, please contact:

This information contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.